Literature DB >> 20166185

Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

Christine Meffre1, Yann Le Strat, Elisabeth Delarocque-Astagneau, Fréderic Dubois, Denise Antona, Jean-Marie Lemasson, Josiane Warszawski, Josiane Steinmetz, Dominique Coste, Jean-François Meyer, Sandrine Leiser, Jean-Pierre Giordanella, René Gueguen, Jean-Claude Desenclos.   

Abstract

To monitor the prevalence of hepatitis B and hepatitis C a cross-sectional survey was conducted in 2004 among French metropolitan residents. A complex sampling design was used to enroll 14,416 adult participants aged 18-80 years. Data collected included demographic and social characteristics and risk factors. Sera were tested for anti-HCV, HCV-RNA, anti-HBc and HBsAg. Data were analyzed with SUDAAN software to provide weighted estimates for the French metropolitan resident population. The overall anti-HCV prevalence was 0.84% (95% CI: 0.65-1.10). Among anti-HCV positive individuals, 57.4% (95% CI: 43.2-70.5) knew their status. Factors associated independently with positive anti-HCV were drug use (intravenous and nasal), blood transfusion before 1992, a history of tattoos, low socioeconomic status, being born in a country where anti-HCV prevalence >2.5%, and age >29 years. The overall anti-HBc prevalence was 7.3% (95%: 6.5-8.2). Independent risk factors for anti-HBc were intravenous drug use, being a man who has sex with men, low socioeconomic status, a stay in a psychiatric facility or facility for the mentally disabled, <12 years of education, being born in a country where HBsAg prevalence >2%, age >29 and male sex. The HCV RNA and HBsAg prevalence were 0.53% (95% CI: 0.40-0.70) and 0.65% (95% CI: 0.45-0.93), respectively. Among HBsAg positive individuals, 44.8% (95% CI: 22.8-69.1) knew their status. Anti-HCV prevalence was close to the 1990s estimates whereas HBsAg prevalence estimate was greater than expected. Screening of hepatitis B and C should be strengthened and should account for social vulnerability. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166185     DOI: 10.1002/jmv.21734

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  59 in total

1.  Occult hepatitis B virus infection in children born to HBsAg-positive mothers after neonatal passive-active immunoprophylaxis.

Authors:  Hanan Foaud; Sahar Maklad; Faten Mahmoud; Hanaa El-Karaksy
Journal:  Infection       Date:  2015-02-10       Impact factor: 3.553

2.  Hepatitis B vaccination status in an at-risk adult population: long-term immunity but insufficient coverage.

Authors:  S Hustache; L Moyroud; L Goirand; O Epaulard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-11       Impact factor: 3.267

Review 3.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 4.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

5.  Hepatitis C virus infection is not an independent risk factor for obstructive lung disease.

Authors:  William A Fischer; Michael B Drummond; Christian A Merlo; David L Thomas; Robert Brown; Shruti H Mehta; Robert A Wise; Greg D Kirk
Journal:  COPD       Date:  2013-07-17       Impact factor: 2.409

Review 6.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

7.  Negative perceptions of hepatitis B vaccination among attendees of an urban free testing center for sexually transmitted infections in France.

Authors:  Lauranne Moyroud; Sarah Hustache; Laurence Goirand; Marianne Hauzanneau; Olivier Epaulard
Journal:  Hum Vaccin Immunother       Date:  2016-12-12       Impact factor: 3.452

Review 8.  Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.

Authors:  Claus Niederau
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

9.  Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study.

Authors:  Leila M M B Pereira; Celina M T Martelli; Regina C Moreira; Edgar Merchan-Hamman; Airton T Stein; Maria Regina A Cardoso; Gerusa M Figueiredo; Ulisses R Montarroyos; Cynthia Braga; Marília D Turchi; Gabriela Coral; Deborah Crespo; Maria Luiza C Lima; Luis Claudio A Alencar; Marcelo Costa; Alex A dos Santos; Ricardo A A Ximenes
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

10.  Socioeconomic status in HCV infected patients - risk and prognosis.

Authors:  Lars Haukali Omland; Merete Osler; Peter Jepsen; Henrik Krarup; Nina Weis; Peer Brehm Christensen; Casper Roed; Henrik Toft Sørensen; Niels Obel
Journal:  Clin Epidemiol       Date:  2013-05-31       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.